CA2521014A1 - Traitement de l'hypertension par association de medicaments - Google Patents

Traitement de l'hypertension par association de medicaments Download PDF

Info

Publication number
CA2521014A1
CA2521014A1 CA002521014A CA2521014A CA2521014A1 CA 2521014 A1 CA2521014 A1 CA 2521014A1 CA 002521014 A CA002521014 A CA 002521014A CA 2521014 A CA2521014 A CA 2521014A CA 2521014 A1 CA2521014 A1 CA 2521014A1
Authority
CA
Canada
Prior art keywords
composition
patient
blood pressure
verapamil
trandolapril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002521014A
Other languages
English (en)
Inventor
Carl J. Pepine
Eileen M. Handberg
Rhonda M. Cooper-Dehoff
Azmi Nabulsi
Robert Altman
Jeff Drajesk
Laura Williams
Peter S. Zilles
Udo F. Legler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
University of Florida Research Foundation Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2521014A1 publication Critical patent/CA2521014A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002521014A 2003-04-01 2004-04-01 Traitement de l'hypertension par association de medicaments Abandoned CA2521014A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45956303P 2003-04-01 2003-04-01
US40507603A 2003-04-01 2003-04-01
US10/405,076 2003-04-01
US60/459,563 2003-04-01
PCT/US2004/010052 WO2004087132A2 (fr) 2003-04-01 2004-04-01 Traitement de l'hypertension par association de medicaments

Publications (1)

Publication Number Publication Date
CA2521014A1 true CA2521014A1 (fr) 2004-10-14

Family

ID=34526057

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002521014A Abandoned CA2521014A1 (fr) 2003-04-01 2004-04-01 Traitement de l'hypertension par association de medicaments

Country Status (3)

Country Link
EP (1) EP1610775A2 (fr)
CA (1) CA2521014A1 (fr)
WO (1) WO2004087132A2 (fr)

Also Published As

Publication number Publication date
WO2004087132A3 (fr) 2005-02-17
EP1610775A2 (fr) 2006-01-04
WO2004087132A2 (fr) 2004-10-14
WO2004087132A8 (fr) 2005-05-06

Similar Documents

Publication Publication Date Title
Calhoun et al. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension
Hermida et al. Chronotherapy of hypertension: administration-time-dependent effects of treatment on the circadian pattern of blood pressure
Epstein et al. Dihydropyridine calcium channel antagonists in the management of hypertension
Bakris et al. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed‐dose combination approaches
Gottwald‐Hostalek et al. Management of hypertension with a fixed‐dose (single‐pill) combination of bisoprolol and amlodipine
Chrysant Using fixed-dose combination therapies to achieve blood pressure goals
Donohue et al. Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: results of a randomized 1-year trial in patients with COPD
US20180311217A1 (en) Methods of treatment and compositions with xanthine oxidase inhibitors
Neutel et al. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements
Snider et al. Long-acting nifedipine in the management of the hypertensive patient
Juif et al. Mitigation of initial cardiodynamic effects of the S1P1 receptor modulator ponesimod using a novel up‐titration regimen
James et al. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension
Rosenstock et al. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non‐responsive to hydrochlorothiazide alone
Sista et al. Pharmacokinetics of a novel diltiazem HCl extended‐release tablet formulation for evening administration
US20160120885A1 (en) Fixed dose combination for pain relief without edema
Sica et al. The antihypertensive efficacy and safety of a chronotherapeutic formulation of propranolol in patients with hypertension
Siddiqui et al. Fixed-dose combination enalapril/nitrendipine: a review of its use in mild-to-moderate hypertension
Talbert Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention
US20050032784A1 (en) Combination drug therapy for treating hypertension
Düsing et al. Sustained Blood Pressure–Lowering Effect of Aliskiren Compared With Telmisartan After a Single Missed Dose
CA2521014A1 (fr) Traitement de l'hypertension par association de medicaments
Lundy et al. Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension
Bakris et al. Comparative antihypertensive efficacy of angiotensin receptor blocker‐based treatment in African‐American and white patients
Neutel et al. Advantages of combination therapy compared with monotherapy
White Angiotensin‐Converting Enzyme Inhibitors in the Treatment of Hypertension: An Update

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20090401